Dr. Michele Ross, Leading Cannabis Voice, Joins NanoSphere Health Sciences Team

written by Raj Shah | June 7, 2018

June 7, 2018 (Source) – *Renowned Advocate and Scientist Takes on Medical Advisor Role for Evolve Formulas*

Dr. Michele Ross, neuroscientist, author and cannabinoid medicine leader, has joined the advisory board for NanoSphere Health Sciences, LLC (CSE: NSHS) (OTC: NSHSF), the biotechnology leader behind the patented NanoSphere Delivery System™, which nano-encapsulates cannabinoid molecules in lipid membranes for transportation through the skin into the bloodstream within minutes. The company currently offers its pioneering product—Transdermal NanoSerum™—under the brand Evolve Formulas, with plans to release intranasal and intraoral products in the coming months.

Dr. Ross brings to the NanoSphere board a wealth of industry knowledge, advocacy experience and insight into particular patient needs. Her work as Founder and Executive Direct of IMPACT Network, a non-profit which focuses on cannabis and women's health, and as CEO of Infused Health, a digital platform which provides educational resources to cannabis patients, has helped consumers around the world and trained the next generation of cannabis healthcare professionals. Dr. Ross entered the cannabis industry as both a scientist and cannabis patient, having been diagnosed with fibromyalgia, neuropathy, and chronic pelvic pain.

In her new role, Dr. Ross will take part in product development and strategy meetings, offer expertise on Evolve Formulas products and co-author scientific papers with NanoSphere's Chief Science Officer, Dr. Richard Kaufman. Dr. Ross will also partake in ambassadorship activities for Evolve Formulas and NanoSphere technology, beginning with a speaking engagement on behalf of the company at the O'Cannabiz Conference and Expo in Toronto this weekend, June 9, covering cannabis and women's issues.

"NanoSphere Health Sciences prides itself on bringing together the best scientific minds to create breakthrough advancements for patients. Dr. Ross becoming a member of our board, and an ambassador of our technology, widens this circle of innovation and excellence while also bringing to the table a unique insight into patient experience. We look forward to working with Dr. Ross to improve our offerings and form mutually beneficial partnerships," Said Robert Sutton, Chairman and CEO of NanoSphere Health Sciences and Evolve Formulas.

"I continuously look for the best cannabis products to meet patients' needs. The NanoSphere Delivery System™ and the Evolve Formulas products bring a new technology to the market that provides one-of-a-kind benefits to those suffering from pain, inflammation, anxiety, distress, seizures and beyond. I am proud to be contributing to the development of NanoSphere's offerings and to further their mission of making cannabis delivery safer and more effective," Said Dr. Michele Ross, Member of the Board of Advisors for NanoSphere Health Sciences.

On behalf of the Board

Robert Sutton, Chairman and CEO

NanoSphere's Commitment to Licensing IP

NanoSphere launched its IP licensing program in 2015 and is entertaining several licensing opportunities via a rigorous evaluation process. For more information about NanoSphere's licensing program, please visit: https://www.nanospherehealth.com/licensing/

About NanoSphere

NanoSphere Health Sciences, LLC, is a biotechnology firm specializing in the creation of the patented NanoSphere Delivery System™, a revolutionary platform using nanotechnology in the biodelivery of supplements, nutraceuticals and over-the-counter medications for the cannabis, pharmaceutical and animal health industries, and beyond. NanoSphere Delivery System™ represents one of the most important developments for advancing the non-invasive and user-friendly delivery of biological agents in over 25 years. For more information on NanoSphere, please visit http://www.nanospherehealth.com.

About Evolve Formulas

Evolve Formulas is the provider of the world's first and only scientifically proven nanoparticle delivery system in cannabis. Evolve's pioneering product, Transdermal NanoSerum™, is a fast-acting, ultra-strength transdermal formula infused with nano-encapsulated cannabis and cannabis extracts. NanoSerum™ immediately penetrates the skin to deliver direct-focused results and intelligently carries a full spectrum of cannabinoids and phytochemicals to receptors throughout the body for systemic healing. Evolve Formula products leverage NanoSphere Health Sciences™ patented NanoSphere Delivery System™. The NanoSphere Delivery System™ is a revolutionary platform using nanotechnology in the biodelivery of supplements, nutraceuticals and over-the-counter medications for the cannabis, pharmaceutical and animal health industries, and

beyond.

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.

Forward Looking Statement Caution

This news release includes forward looking statements that are subject to assumptions, risks and uncertainties. Statements in this news release which are not purely historical are forward looking statements, including without limitation any statements concerning the Company's intentions, plans, estimates, expectations or beliefs regarding the future. Although the Company believes that any forward looking statements in this news release are reasonable, there can be no assurance that any such forward looking statements will prove to be accurate. The Company cautions readers that all forward looking statements, including without limitation those relating to the Company's future operations and business prospects, are based on assumptions none of which can be assured, and are subject to certain risks and uncertainties that could cause actual events or results to differ materially from those indicated in the forward looking statements. Readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance on forward looking statements. Any forward looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward looking statements, or to update the reasons why actual events or results could or do differ from those projected in the forward looking statements, whether as a result of new information, future events or otherwise.